Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Sedor

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical and Translational Radiation Oncology|January 7, 2025
Corrigendum to "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery" [Clin. Transl. Radiat. Oncol. 43 (2023) 100678]Erin M McClure, Geoffrey Sedor, Yuxuan Jin, et al.
Clinical and Translational Radiation Oncology|October 2, 2023
Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgeryErin M McClure, Geoffrey Sedor, Yuxuan Jin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2021
Letter ResponseGeoffrey Sedor, Jacob G Scott, Michael W Kattan, et al.
Advances in Radiation Oncology|January 8, 2025
Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin CancerErin M McClure, Geoffrey Sedor, Mairead Moloney, et al.
The Lancet. Oncology|November 4, 2021
Radiotherapy with genomic-adjusted radiation dose - Authors' replyJacob G Scott, Geoffrey Sedor, Jessica A Scarborough, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2021
Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation DoseG Daniel Grass, Jacob G Scott, Geoffrey Sedor, et al.
The Lancet. Oncology|August 7, 2021
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysisJacob G Scott, Geoffrey Sedor, Patrick Ellsworth, et al.
American Journal of Clinical Oncology|April 30, 2020
Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot StudyShireen Parsai, Aditya Juloori, Geoffrey Sedor, et al.
American Journal of Clinical Oncology|January 6, 2021
Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic SarcomaShireen Parsai, Geoffrey Sedor, Timothy D Smile, et al.
Clinical and Translational Radiation Oncology|August 16, 2024
CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experienceAlbert Lee, Jared Pasetsky, Elizaveta Lavrova, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical and Translational Radiation Oncology|January 7, 2025
Corrigendum to "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery" [Clin. Transl. Radiat. Oncol. 43 (2023) 100678]Erin M McClure, Geoffrey Sedor, Yuxuan Jin, et al.
Clinical and Translational Radiation Oncology|October 2, 2023
Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgeryErin M McClure, Geoffrey Sedor, Yuxuan Jin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2021
Letter ResponseGeoffrey Sedor, Jacob G Scott, Michael W Kattan, et al.
Advances in Radiation Oncology|January 8, 2025
Image Guidance is Associated with Improved Freedom From Recurrence After Superficial Radiation Therapy for Nonmelanoma Skin CancerErin M McClure, Geoffrey Sedor, Mairead Moloney, et al.
The Lancet. Oncology|November 4, 2021
Radiotherapy with genomic-adjusted radiation dose - Authors' replyJacob G Scott, Geoffrey Sedor, Jessica A Scarborough, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2021
Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation DoseG Daniel Grass, Jacob G Scott, Geoffrey Sedor, et al.
The Lancet. Oncology|August 7, 2021
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysisJacob G Scott, Geoffrey Sedor, Patrick Ellsworth, et al.
American Journal of Clinical Oncology|April 30, 2020
Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot StudyShireen Parsai, Aditya Juloori, Geoffrey Sedor, et al.
American Journal of Clinical Oncology|January 6, 2021
Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic SarcomaShireen Parsai, Geoffrey Sedor, Timothy D Smile, et al.
Clinical and Translational Radiation Oncology|August 16, 2024
CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experienceAlbert Lee, Jared Pasetsky, Elizaveta Lavrova, et al.
Pageof 2